A Multicenter, Randomized, Double-blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of CYP-001 in Combination With Corticosteroids vs Corticosteroids Alone for the Treatment of High-Risk Acute Graft Versus Host Disease
Latest Information Update: 29 Jan 2025
At a glance
- Drugs CYP 001 (Primary) ; Methylprednisolone (Primary) ; Prednisone (Primary)
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- Sponsors Cynata Therapeutics; FUJIFILM Corporation
Most Recent Events
- 24 Jan 2025 Planned End Date changed from 31 Dec 2026 to 30 Jun 2027.
- 24 Jan 2025 Planned primary completion date changed from 30 Apr 2025 to 31 Oct 2025.
- 10 Aug 2023 Planned End Date changed from 31 Mar 2026 to 31 Dec 2026.